NuSep tries NxGen
Thursday, 02 October, 2008
Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.
Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.
This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.
NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.
Air pollutant exposure linked to glaucoma, cataracts and suicide
People who are exposed to high levels of air pollution are more likely to develop glaucoma and...
Could this 'nanobone' material allow children to regrow bone?
Australian scientists believe they have found an alternative to invasive bone graft procedures in...
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
